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INTRODUCTION
Hemophagocytic lymphohistiocytosis (HLH) is an unusu-
al disorder characterized by persistent unexplained fever,
hepatic dysfunction, massive hepatosplenomegaly, pancy-
topenia, hypertriglyceridemia, hypofibrinogenemia, and
hemophagocytosis in the bone marrow, liver, spleen, or lymph
nodes (1-3). HLH frequently occurs in children less than 2
yr of age as a familial autosomal recessive disorder (4). It has
also been associated with infectious or malignant diseases in
a secondary form of the disorder.
The familial form of HLH progresses rapidly and is uni-
formly fatal without treatment, but some successes have
been reported for secondary HLH patients that are Epstein-
Barr virus (EBV) positive. Dexamethasone, etoposide, and
cyclosporin A (CsA)-based protocols with additional intrathe-
cal methotrexate instillation have been used for the treatment
to improve survival (5). For secondary HLH, because of its
feature of cytokine flooding and the resultant hemophagocy-
tosis and its EBV association, steroid, intravenous immuno-
globulin (IVIG), and CsA have been added to the cytotoxic
agents used for treatment. Although diverse therapeutic
regimens including cytotoxic therapy and immunomodula-
tors have been tried, no standard treatment regimen is as
yet established.
The cyclophosphamide, doxorubicin, vincristine, and pred-
nisone (CHOP) regimen has been shown to be the most
effective regimen for the treatment of malignant lymphomas
in which monoclonal proliferation of lymphocytes prevails.
As some core features of pathogenesis are common in HLH
and malignant lymphomas, the CHOP regimen is worthy
to be tested. Here we have investigated the efficacy and tox-
icity of the CHOP regimen for the treatment of HLH.
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Treatment Outcomes with CHOP Chemotherapy in Adult Patients with
Hemophagocytic Lymphohistiocytosis
The objective of the current study was to investigate the treatment outcomes for
the use of cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP)
chemotherapy in adult patients with hemophagocytic lymphohistiocytosis (HLH).
Seventeen HLH patients older than 18 yr of age were treated with CHOP chemother-
apy. A response evaluation was conducted for every two cycles of chemotherapy.
With CHOP chemotherapy, complete response was achieved for 7/17 patients
(41.2%), a partial response for 3/17 patients (17.6%), and the overall response rate
was 58.8%. The median response duration (RD) was not reached and the 2-yr RD
rate was 68.6%, with a median follow-up of 100 weeks. Median overall survival
(OS) was 18 weeks (95% CI, 6-30 weeks) and the 2-yr OS rate was 43.9%. Report-
ed grade 3 or 4 non-hematological toxicities were increased serum liver enzyme
levels and stomatitis. Grade 3 or 4 hematological toxicities were leukopenia (50.8%),
anemia (20%), and thrombocytopenia (33.9%). Neutropenic fever was observed
in 21.6% of patients (14/65 cycles), and most of the cases were resolved with sup-
portive care including treatment with broad-spectrum antibiotics. CHOP chemother-
apy seems to be effective in adult HLH patients and the toxicities are manageable.
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Patients and diagnosis
From March 1999 through December 2004, 46 patients
older than 18 yr of age were diagnosed with HLH at four
medical institutions in South Korea. Among these cases, 17
patients were treated with CHOP chemotherapy. A diagno-
sis of HLH was made according to the revised diagnostic crite-
ria of the HLH study group of the Histiocyte Society (Table
1) (1). Informed consent was obtained from each patient.
The possible association of HLH with EBV was analyzed
by the use of serological assays. Serological tests were per-
formed with IgG and IgM antibodies against the EBV viral
capsid antigen (VCA), early antigen (EA), and EBV nuclear
antigen (EBNA) using the enzyme-linked immunosorbent
assay (ELISA) method. An active EBV infection was sug-
gested when patients with a positive anti-EBNA antibody
exhibited one of the following conditions: 1) anti-VCA IgG
antibody titer over 1:640, 2) paired anti-VCA IgG titer ris-
ing fourfold, or 3) anti-EA IgG titer greater than 1:40 (2).
A cytomegalovirus (CMV) antigenemia test and serological
analyses for viruses, including human herpesvirus-6, human
simplex virus type 1/2, varicella zoster virus, parvovirus B19,
and CMV in the serum were also performed.
Treatment regimen
Seventeen patients were initially treated with CHOP (750
mg/m2 cyclophosphamide intravenously on day 1; 50 mg/m2
doxorubicin intravenously on day 1; 1.4 mg/m2 vincristine,
maximal dose of 2 mg, on day 1; and 40 mg/m2 prednisone
for five days) chemotherapy. Reductions by 25% in the dose
of cyclophosphamide and doxorubicin were made for all suc-
ceeding courses of CHOP if grade 4 hematological toxicities
or grade 3/4 non-hematological toxicities were observed in
the prior course of chemotherapy. Chemotherapy was repeat-
ed every 3 to 4 weeks for a total of six to eight cycles in respond-
ing patients. If the neutrophil count was lower than 1,500/ L
or the platelet count was lower than 100,000/ L, the cycle
was delayed for up to two weeks, or treatment was termi-
nated when chemotherapy was delayed for more than two
weeks. The patients that had an human leukocyte antigen
(HLA)-matched sibling donor underwent stem cell trans-
plantation (SCT) at any treatment schedule. However, some
patients that had an HLA-matched sibling donor did not
undergo SCT due to early death or refusal to undergo SCT.
Evaluation of response
Complete response (CR) was considered if there was unequiv-
ocal resolution of clinical signs and symptoms, as well as
normalization of the laboratory findings, particularly the
serum level of ferritin. Partial response (PR) was defined as
a persistent fever and other symptoms of HLH or an abnor-
mally high level of serum ferritin in the absence of defini-
tive symptoms. All other cases were defined as no response
(NR). The evaluation of response was performed after every
two cycles of CHOP chemotherapy.
Statistical analysis
The response duration (RD) was calculated from the time
of the first documented response to the time of disease pro-
gression or death. The overall survival (OS) was calculated
from the beginning of treatment to the time of analysis or
death, and calculated using the Kaplan-Meier method. Sta-
tistical significance was determined at a level of p<0.05. The
software package SPSS for Windows (version 13.0, SPSS.
Chicago, IL, U.S.A.) was used for the statistical analysis.
RESULTS
Patient characteristics and laboratory data
The patient characteristics, including the initial clinical
and laboratory data, are detailed in Table 2. The age of the
patients ranged from 18 to 77 yr, with a median age of 38 yr,
and nine patients were male and eight patients were female.
Seven patients had a malignant lymphoma (three with a
diffuse large B cell lymphoma, two with a peripheral T cell
lymphoma, and two with an extranodal NK/T cell lym-
phoma). Five patients were associated with EBV infection.
No etiology was found in the remaining five patients. Bone
marrow involvement of the lymphoma cells was detected in
four patients among the seven patients with malignant lym-
phoma.
While the most common presenting symptom was fever
(17 cases, 100%), hepatosplenomegaly, lymphadenopathy,
increased level of serum lactate dehydrogenase (range, 635-
4,541 IU/L; normal range, 180-460 IU/L), and increased
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Table 1. Diagnostic criteria for hemophagocytic lymphohistiocy-
tosis
Familial disease/known genetic defect
Clinical and laboratory criteria (five of eight criteria)
Fever
Splenomegaly
Cytopenia greater than or equal to two cell lines
Hemoglobin <9.0 g/dL (below 4 weeks <10.0 g/dL)
Platelets <100×10
9/L
Neutrophils <1.0×10
9/L
Hypertriglyceridemia and/or hypofibrinogenemia (fasting triglycerides
≥3 mM/L; fibrinogen <1.5 g/L) 
Ferritin ≥500 g/L
sCD25 ≥2,400 U/mL
Decreased or absent natural killer-cell activity
Hemophagocytosis in bone marrow, cerebrospinal fluid, or lymph nodesserum ferritin level (range, 500-5114 ng/mL; normal range,
15-332 ng/mL) were the fundamental findings for the HLH
patients. Thrombocytopenia (14 cases, 82.4%) was a com-
mon finding at the initial diagnosis compared to anemia (6
cases, 35.3%) and leukopenia (4 cases, 23.5%). Jaundice,
elevated levels of serum liver enzymes, coagulopathy with a
prolonged prothrombin time and/or an activated partial
thromboplastin time and hypertriglyceridemia were also
noted in more than half of the patients. In all cases, bone
marrow aspiration and a biopsy revealed varying degrees of
histiocyte proliferation with active hemophagocytosis.
Treatment outcomes
In the current study, a total of 65 courses of chemotherapy
were administered, with a median of three courses (range,
1-8) given per patient. Six patients received one or two cours-
es, four patients received three courses, six patients received
six courses, and only one patient received eight courses of
chemotherapy. One (case 8) out of seven patients that achiev-
ed CR received only two courses of chemotherapy because
the patient was offered treatment with high-dose chemother-
apy followed by stem cell transplantation.
Based on intent-to-treat analysis, the overall response rate
was 58.8% (10 patients: 5 patients with a malignant lym-
phoma, three patients with EBV, and two patients with an
unknown etiology). Seven patients (41.2%) achieved CR
and three patients (17.6%) achieved PR. Six of seven patients
who achieved CR are currently alive. Five of seven patients
(71.4%) with a malignant lymphoma, three of five patients
(60%) with EBV, and two of five patients (40%) with an
unknown etiology had a response (Table 3). The median fol-
low-up duration was 100 weeks (range 16-272 weeks); the
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No. of patients (%)
Total CR PR NR NE
Characteristics
Overall 17 7 (41.2) 3 (17.6) 4 (23.5) 3 (17.6)
Underlying cause
Malignant lymphoma 7 3 (42.9) 2 (28.6) 2 (28.6) 0 (0)
EBV 5 3 (60) 0 (0) 1 (20) 1 (20)
Unknown  5 1 (20) 1 (20) 1 (20) 2 (40)
Table 3. Response to treatment with CHOP chemotherapy in
patients with HLH
P
r
o
b
a
b
i
l
i
t
y
1.0
0.8
0.6
0.4
0.2
0.0
0 48 96 144 192 240 288
Week
Fig. 1. Two-year response duration rate 68.6% (A) and overall survival rate 43.9% (B) for adult patients with hemophagocytic lymphohis-
tiocytosis.
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Characteristics No. of patients (%)
Age, years 38, range 18-77
60 yr 5 (29.4)
<60 yr 12 (70.6)
Sex
Male/Female 9 (52.9)/8 (47.1)
Underlying cause
Malignant lymphoma 7 (41.2)
EBV infection 5 (29.4)
Unknown etiology 5 (29.4)
Persistent fever 17 (100)
Lymphadenopathy 11 (64.7)
Hepatosplenomegaly 14  (82.4)
Pleural effusion  6 (35.3)
Neutrophil count <1.0×10
9/L 4 (23.5)
Hemoglobin <9.0 g/dL 6 (35.3)
Platelets < 100×10
9/L 14 (82.4)
Hypofibrinogenemia 8 (47.1)
Hypertriglyceridemia 10 (58.8)
Increased AST/ALT 11 (64.7)
Increased LDH 16 (94.1)
Serum ferritin ≥500 g/L 17  (100)
Prolonged PT/aPTT 11 (64.7)
Increased total bilirubin 11 (64.7)
Table 2. Patient characteristics and laboratory data for 17 patients
with HLH
HLH, hemophagocytic lymphohistiocytosis; EBV, Ebstein-Barr virus;
AST, aspartate transaminase; ALT, alanine transaminase; LDH, lactate
dehydrogenase; PT, prothrombine time; aPTT, activated partial throm-
boplastin time.
EBV, Ebstein-Barr virus; CHOP, cyclophosphamide, adviamycin, vin-
cristine and prednisolone; HLH, hemophagocytic lymphohistiocytosis;
CR, complete response; PR, partial response; NR, no response; NE,
not evaluable.median RD was not reached, and the 2-yr RD rate was 68.6%.
The median OS was 18 weeks (95% CI, 6-30 weeks) and
the 2-yr OS rate was 43.9% (Fig. 1). 
Nine patients died within 18 weeks. Among these early
deaths, three patients achieved PR and six achieved NR with
CHOP chemotherapy. The underlying disease was a malig-
nant lymphoma for case 3 and an unknown etiology for cases
14 and 16 (Table 4), and all of these patients received salvage
chemotherapy (dexamethasone, high-dose cytarabine and
cisplatin [DHAP]) or (etoposide, methylprednisolone, high-
dose cytarabine and cisplatin [ESHAP]), but all of the pati-
ents died within 16 weeks due to disease progression. Cases
4 and 8 that had an underlying disease of malignant lym-
phoma and EBV underwent allogeneic SCT; however, all of
the patients died from infection (Table 4).
Toxicities
All 17 patients were assessable for toxicities associated with
CHOP chemotherapy. Dose reductions were required for six
patients (35.3%; a result of grade 4 hematological toxicity
in five patients and a grade 4 hepatotoxicity in one patient).
Ten chemotherapy cycles (15.4%) were delayed due to a
hematological toxicity or patient noncompliance. A few
patients required a dose reduction of full-dose CHOP, such
that 95.7% of the intended dose was delivered throughout
the chemotherapies. 
Non-hematological toxicities were predominantly grade
1 or 2. The most frequent non-hematological toxicity was
hepatotoxicity. Gastrointestinal toxicities were also common,
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No.
Sex/
age
Underlying
disease
CTx
cycle
Response
Response
duration (wk)
OS
(wk)
Salvage
Tx
Last event
1 M/30 Lymphoma 6 CR after 2nd cycle 94 199 No Alive
2 F/18 Lymphoma 6 CR after 2nd cycle 261 277 No Alive
3 M/51 Lymphoma 3 PR after 2nd cycle 1 12 DHAP Death d/t Ds progression
4 M/39 Lymphoma 2 NR NE 8 AlloSCT Death d/t pneumonia 
after alloSCT
5 F/41 Lymphoma 8 CR after 2nd cycle 223 234 No Alive
6 M/72 Lymphoma 6 PR after 2nd cycle 3 40 No F/U loss
7 F/64 Lymphoma 2 NR NE 4 No Death d/t Ds progression
8 M/21 EBV 2 PR after 2nd cycle 3 18 AlloSCT Death d/t sepsis 
CR after 4th cycle
9 M/38 EBV 3 NR NE 8 No Death d/t Ds progression
10 F/60 EBV 6 CR after 2nd cycle 71 74 No Alive
11 M/68 EBV 1 NE NE 4 No F/U loss
12 F/77 EBV 6 CR after 2nd cycle 147 151 No Alive
13 F/36 Unknown 6 CR after 2nd cycle 116 124 No Alive
14 F/25 Unknown 3 PR after 2nd cycle 8 16 ESHAP Death d/t Ds progression
15 M/68 Unknown 1 NE NE 8 No Death d/t Ds progression
16 M/28 Unknown 1 NE NE 6 DHAP Death d/t Ds progression
17 F/18 Unknown 3 NR NE 12 No Death d/t Ds progression
Table 4. Treatment outcomes 
Death d/t Ds progression.
CTx, chemotherapy; wk, week; Tx, treatment; OS, overall survival; CR, complete response; PR, partial response; NR, no response; DHAP, dexam-
ethasone, cytarabine and cisplatin; NE, not evaluable; AlloSCT, allogeneic stem cell transplantation; d/t, due to; Ds, disease; F/U, follow-up; EBV,
Epstein-Barr virus; ESHAP, etoposide, methylprednisolone, high-dose cytarabine and cisplatin.
Toxicity
Grade 1
(No.)
Grade 2
(No.)
Grade 3
(No.)
Grade 4
(No.)
AST/ALT 3 4 1 3
Total bilirubin 3 1 2 2
Serum creatinine --- -
Anorexia 12 4 1 -
Nausea/vomiting 11 2 1 -
Stomatitis 2 2 3 -
Diarrhea 1 1 --
Constipation 1 ---
Peripheral neuropathy 2 2 --
Arthralgia/myalgia 4 1 --
Asthenia 2 6 --
Dizziness - 11-
Insomnia - 1 --
Table 5. Non-hematologic toxicities of 65 courses administered
Toxicity
Grade 1
(No.)
Grade 2
(No.)
Grade 3
(No.)
Grade 4
(No.)
Leukopenia 5 9 12 21
Neutropenia 4 5 9 24
Anemia 7 14 10 3
Thrombocytopenia 1 4 15 7
Febrile neutropenia -- 77
Table 6. Hematologic toxicities of 65 courses administered
AST, aspartate transaminase; ALT, alanine transaminase.particularly anorexia, nausea/vomiting and stomatitis, which
were well controlled with supportive care. Transient diar-
rhea and constipation were also reported. No renal toxicity
was observed (Table 5).
The hematological toxicities are shown in Table 6. Grade
3 or 4 leukopenia occurred after 33 courses (51.8%) and
grade 3 or 4 neutropenia after 31 courses (50.7%) of chemo-
therapy. Grade 3 or 4 anemia and thrombocytopenia were
observed after 13 (20%) and 22 (33.9%) courses of chemo-
therapy, respectively. There were grade 3 or 4 neutropenic
fevers after 14 courses of chemotherapy (21.6%). Case 6 and
10 showed a splenic hemorrhage and pulmonary alveolar
hemorrhage after the first cycle of chemotherapy, respective-
ly; however, these patients improved with supportive man-
agement and could complete six cycles of chemotherapy
safely.
Serum LDH level
While a baseline check-up of serum LDH, ferritin, triglyc-
eride and fibrinogen levels were performed, only the serum
LDH level could be checked serially with each cycle of
chemotherapy. Fig. 2 shows the serial serum LDH level in
patients who achieved CR compared with PR or NR. The
serum LDH level decreased earlier (only after the first cycle
of chemotherapy) in patients with CR. On the other hand,
serum LDH sustained a high level in spite of continuous
chemotherapy in patients with PR or NR.
DISCUSSION
Although etoposide-containing immunochemotherapy
has become a recommended treatment for childhood EBV-
HLH (3), treatment results for adult cases have seldom been
reported. In addition, treatment strategies for lymphoma-
associated HLH (LAHLH) have not yet been established.
Miyahara et al. previously reported the use of standard
cytotoxic regimens (CHOP±L-asparaginase or etoposide)
on 7 patients with peripheral B-cell LAHLH (2) and the
reported outcome was poor (only one patient achieved CR
and had disease-free survival). In this study, most patients
were elderly (the median age was 67 yr with a range of 48-
75 yr). Considering that a patient age older than 30 yr is an
adverse risk factor (6), this study reminds us of the impor-
tance of age. In the current study, the overall response rate
was 58.8%; seven of 17 patients with HLH achieved CR and
most of the patients (six patients) are still alive. Thus, it is
conceivable that the better treatment outcomes of the cur-
rent study, as compared with the outcomes reported by Miya-
hara et al., are due to the relatively younger aged population
of the patients in the current study (median age 38 yr).
EBV-HLH often mimics a T-cell lymphoma biologically
(7). EBV-HLH should be considered as a malignant entity
and should be treated with intensive cytotoxic chemothera-
py or stem cell transplantation (7-12). As deaths resulting
from EBV-HLH are largely caused by the cytokine storm
that results in multiple organ failure (7), to avoid this risk,
early introduction of treatment is important to achieve a good
result in patients with EBV-HLH. The treatment objective
is to control the cytokine storm induced by virus infection
and to eradicate the proliferating virus-infected cells. Thus
far, this can be solely achieved by treatment with cytotoxic
agents such as etoposide (7). Imashuku et al. reported that
43 of 47 patients had a response (34 CR and 9 PR) and a 4-
yr OS rate of 78.3±6.7% when introducing an etoposide-
containing regimen to pediatric patients with EBV-HLH
(13), suggesting etoposide has a potential of survival time
prolongation. However, results for adult patients with EBV-
HLH who were treated with an etoposide-based regimen
have been seldom reported. Recently, Imashuku et al. report-
ed that seven young adults patients with EBV-HLH receiv-
ing etoposide early after diagnosis showed a 2.5-yr survival
of 85.7% (14). These investigators concluded that early instal-
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Fig. 2. Serial serum LDH level. (A) HLH patients who showed CR after CHOP chemotherapy. (B) HLH patients who showed PR or NR
after CHOP chemotherapy. 
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Blation of etoposide is an effective way to treat EBV-HLH in
young adults as well as in children. However, this study in-
cluded a small number of young adult patients with EBV-
HLH, and was not conclusive for adult patients. A success-
ful treatment with CPT-11 and adriamycin for HLH associ-
ated with intravascular lymphomatosis has also been report-
ed to extend the drug choice (15). Considering that CHOP
regimen is a standard chemotherapy regimen for aggressive
non-Hodgkin’s lymphoma, CHOP can be considered as an
effective tool to treat HLH combined with malignant lym-
phoma. For EBV-HLH, immunossupressive agents (cyclophos-
phamide, vincristine, and prednisolone) can decrease hyper-
cytokinemia, which causes early mortality, and a cytotoxic
agent such as adriamycin can kill the EBV-infected hemo-
phagocytic cells. In this study, 3 of the 5 patients with EBV-
HLH that were treated with CHOP chemotherapy showed
a CR, and at least 2 patients were still alive at the time of
analysis. Therefore, although based on a small number of
patients in the current study, CHOP chemotherapy shows a
therapeutic potential in adult patients with EBV-HLH. 
The lack of solid data on standard treatment protocols for
adult patients with HLH is, in part, due to the rare incidence
of the disease. As the difference in the therapeutic efficacy
between CHOP and the etoposide-based regimen is not yet
clear, more multi-center trials are needed to determine a more
appropriate regimen to use in adult patients with HLH.
In the current study, the serum LDH level was checked
serially after each cycle of CHOP chemotherapy and showed
very early normalization in patients who achieved CR com-
pared with patients who achieved PR or NR. Based on this
result, it may be postulated that serum LDH levels could be
used as a surrogate marker to determine whether to proceed
or not with CHOP chemotherapy.
In conclusion, CHOP chemotherapy showed a relatively
favorable activity for adult patients with HLH and the toxi-
cities were manageable. Because of the small sample size in
this current study, further studies that include a large num-
ber of patients are needed.
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